Preclinical Contract Research Services
ImQuest BioSciences is a preclinical contract research and development company that provides service to evaluate the potential of new and novel pharmaceutical products for the treatment and prevention of infectious disease, cancer and inflammatory disease.
As part of our ImQuest SUCCESS platform, we provide expert laboratory research services to define the efficacy and toxicity of pharmaceutical products and specialize in the development of small molecules, natural products, biologics, antimicrobial peptides, therapeutic antibodies and vaccines.
We have expertise in services for antiviral, antimicrobial, and anticancer product development, in vitro toxicology assessment and pharmaceutical product characterization and formulation.
We are committed to earning our client's trust and building long term relationships through collaboration, unwavering commitment to quality science and consistent and effective communication. We understand that each product and each client is unique and we strive to provide effective solutions. Learn More.
Anti-Dengue antibodies enhance Zika virus infection
As part of our ViroSENS program, ImQuest BioSciences has established an anti-Zika virus cytoprotection assay for multiple strains of Zika virus in multiple cell types.
HIV Research For Prevention (HIV-R4P)
October 18-21, 2016
American Association of Pharmaceutical Science
November 13-17, 2016
Meet the Team
Anthony Ham, Ph.D
Director, Formulation Science Services
Dr. Ham is the Director of Formulation and Delivery Services at ImQuest. He received his B.S. from the University of Illinois in Chemical Engineering